TrialPath
Recruiting

French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis

NCT06147843 · University Hospital, Limoges
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
ALS is the most frequent adult onset motor neuron disease and is highly variable in terms of clinical features, genetics, and neuropathology. A large body of evidence has demonstrated the importance of weight loss at the time of diagnosis and during disease progression. Weight loss affects between one and two-thirds of patients and is adversely associated with survival. High caloric nutrition was able to slow weight loss and prolong survival in fast progressing ALS patients. Pathophysiological mechanisms underlying weight loss remain unknown because high-quality cohort data collecting clinical features, genetics, omics, and imaging related to the metabolic and disease status of patients are lacking. The investigators hypothesize that weight loss in ALS patients is biologically driven through specific pathways. The investigators propose an innovative and ambitious multidisciplinary project to structure a large French-German cohort to identify markers associated with weight loss. The investigators aim at identifying the biological correlates of weight loss to disentangle the mechanistic basis of this critical symptom and to determine clinical and biological profiles along with their impact on disease progression and survival.
Eligibility criteria
Inclusion Criteria: * Incident cases included at the time of diagnosis with a definite, probable, probable laboratory-supported, or possible ALS according to El Escorial revised criteria and Gold Coast criteria for early diagnosis. * Incident ALS cases identified and followed-up in the participant ALS \& Other Motor Neuron Diseases Referral Centres: seven in France and two in Germany. * Patients who signed the informed consent form. * Adults aged \>18 years old Exclusion Criteria: * Inability to understand the requirements of the protocol. * Cognitive inability to sign and comprehend the informed consent form. * Patients who will not accept Riluzole therapy during their follow-up.
Study design
Enrollment target: 1000 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2024-09-17
Estimated completion: 2029-09-30
Last updated: 2026-08-06
Interventions
Other: Blood sample
Primary outcomes
  • • Survival (every 6 month until 18 months of follow up)
Sponsor
University Hospital, Limoges · other
With: National Research Agency, France, Centre de Recherche en biomédecine de Strasbourg INSERM UMR-S1118, Paris Brain Institute (ICM), Institut National de la Santé et de la Recherche Médical - délégation Grand Ouest INSERM U1253, Klinik für Neurologie, Universitäts- und Rehabilitationskliniken Ulm (RKU), Centre de Données Cliniques et de Recherche CDCR, UMR Inserm U1253-IBRain-Neurogénétique et Physiopathologie Neuronale, France Cohorte
Contacts & investigators
ContactPhilippe COURATIER, Pr · contact · philippe.couratier@chu-limoges.fr · 05 55 05 15 69
ContactAndrea ERAZO ALEMAN, Dr · contact · DaniellsAndrea.ERAZOALEMAN@chu-limoges.fr
InvestigatorPhilippe COURATIER, Professor · principal_investigator, University Hospital, Limoges
All locations (9)
CHU de LilleRecruiting
Lille, France
Limoges University HospitalRecruiting
Limoges, France
Hôpital de la TimoneRecruiting
Marseille, France
Hôpital Gui ChauliacRecruiting
Montpellier, France
CHU de NiceRecruiting
Nice, France
Hôpital de la Pitié SalpêtrièreRecruiting
Paris, France
CHU de ToursRecruiting
Tours, France
Klinik für Medizinische Hochschule Hannover Carl-Neuberg-Str. 1Not Yet Recruiting
Hanover, Allemagne, Germany
Klinik für Neurologie, Universitäts- und Rehabilitationskliniken Ulm (RKUNot Yet Recruiting
Ulm, Allemagne, Germany